Tags

Type your tag names separated by a space and hit enter

Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy.
Rheumatol Int. 2014 Feb; 34(2):221-5.RI

Abstract

The aim of this study was to evaluate the effects of bosentan on plasma endothelin-1 (ET-1) and nitric oxide (NO) as pulmonary hypertension (PH)-associated biochemical markers in patients with systemic sclerosis (SSc). Twenty-four SSc patients receiving bosentan for 24 weeks were registered in this prospective observational study. Ten patients were complicated with clinically suspected PH. Plasma levels of ET-1 and NO were assessed at baseline and after 24 weeks of treatment in SSc patients and in 15 healthy controls. Plasma levels of ET-1 and NO at baseline were significantly higher in SSc patients than in healthy controls (p < 0.000), and they were also significantly higher in SSc patients with PH than in those without PH (p < 0.01). Plasma ET-1 levels were significantly decreased after 24 weeks of bosentan therapy (p < 0.0001), and ET-1 levels of SSc patients with PH decreased to a level comparable to that in patients without PH. In the 10 SSc patients with PH, changes in plasma ET-1 levels during the 24 weeks of the study were significantly larger in the 5 patients whose functional class (FC) improved than in the 5 patients whose FC was unchanged (p < 0.05). Plasma NO levels were also slightly decreased in SSc patients after 24 weeks of bosentan therapy. Plasma ET-1 levels could reflect the presence and severity of PH in SSc patients. Additionally, changes in plasma ET-1 levels may indicate the response to bosentan therapy in SSc patients with PH.

Authors+Show Affiliations

Department of Public Health, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan, shin-ya@hotmail.co.jp.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

24071933

Citation

Kawashiri, Shin-ya, et al. "Improvement of Plasma Endothelin-1 and Nitric Oxide in Patients With Systemic Sclerosis By Bosentan Therapy." Rheumatology International, vol. 34, no. 2, 2014, pp. 221-5.
Kawashiri SY, Ueki Y, Terada K, et al. Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy. Rheumatol Int. 2014;34(2):221-5.
Kawashiri, S. Y., Ueki, Y., Terada, K., Yamasaki, S., Aoyagi, K., & Kawakami, A. (2014). Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy. Rheumatology International, 34(2), 221-5. https://doi.org/10.1007/s00296-013-2861-6
Kawashiri SY, et al. Improvement of Plasma Endothelin-1 and Nitric Oxide in Patients With Systemic Sclerosis By Bosentan Therapy. Rheumatol Int. 2014;34(2):221-5. PubMed PMID: 24071933.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy. AU - Kawashiri,Shin-ya, AU - Ueki,Yukitaka, AU - Terada,Kaoru, AU - Yamasaki,Satoshi, AU - Aoyagi,Kiyoshi, AU - Kawakami,Atsushi, Y1 - 2013/09/27/ PY - 2011/08/04/received PY - 2013/09/02/accepted PY - 2013/9/28/entrez PY - 2013/9/28/pubmed PY - 2014/9/30/medline SP - 221 EP - 5 JF - Rheumatology international JO - Rheumatol. Int. VL - 34 IS - 2 N2 - The aim of this study was to evaluate the effects of bosentan on plasma endothelin-1 (ET-1) and nitric oxide (NO) as pulmonary hypertension (PH)-associated biochemical markers in patients with systemic sclerosis (SSc). Twenty-four SSc patients receiving bosentan for 24 weeks were registered in this prospective observational study. Ten patients were complicated with clinically suspected PH. Plasma levels of ET-1 and NO were assessed at baseline and after 24 weeks of treatment in SSc patients and in 15 healthy controls. Plasma levels of ET-1 and NO at baseline were significantly higher in SSc patients than in healthy controls (p < 0.000), and they were also significantly higher in SSc patients with PH than in those without PH (p < 0.01). Plasma ET-1 levels were significantly decreased after 24 weeks of bosentan therapy (p < 0.0001), and ET-1 levels of SSc patients with PH decreased to a level comparable to that in patients without PH. In the 10 SSc patients with PH, changes in plasma ET-1 levels during the 24 weeks of the study were significantly larger in the 5 patients whose functional class (FC) improved than in the 5 patients whose FC was unchanged (p < 0.05). Plasma NO levels were also slightly decreased in SSc patients after 24 weeks of bosentan therapy. Plasma ET-1 levels could reflect the presence and severity of PH in SSc patients. Additionally, changes in plasma ET-1 levels may indicate the response to bosentan therapy in SSc patients with PH. SN - 1437-160X UR - https://www.unboundmedicine.com/medline/citation/24071933/Improvement_of_plasma_endothelin_1_and_nitric_oxide_in_patients_with_systemic_sclerosis_by_bosentan_therapy_ L2 - https://dx.doi.org/10.1007/s00296-013-2861-6 DB - PRIME DP - Unbound Medicine ER -